Anyone that has been following the debacle between Relmada Therapeutics and Laidlaw & Company will be happy to know that a U.S. federal court has issued an order in favor of Relmada Therapeutics. Specifically, the U.S. District Court for the District of Nevada has issued a restraining order against Laidlaw & Company, as well as an injunction to prevent them from continuing to spread false information.
Laidlaw and its principals, Matthew Eitner and James Ahern, have a history of spreading false information and using generally deceitful tactics to try and bully other companies into following their lead. As hopeless as the situation may feel sometimes as an outsider looking in, it’s nice to see that sometimes the courts are willing to take a stand against big business and protect the underdog. In the case of Relmada Therapeutics, the dispute originally took place after Laidlaw made attempts to seize control of Relmada Therapeutics. While it’s true that Laidlaw did at one point serve as an investment banker for Relmada, it’s clear that their two business philosophies are inherently incompatible.
Luckily, the Chief Executive Officer of Relmada Therapeutics agrees with me, as he is quoted as saying that his company’s interests clearly do not coincide with Laidlaw & Company’s. If you’ve never heard the name Laidlaw & Company, you might be forgiven for thinking this is just some overblown dispute between two competing companies. In truth, this dispute gets to a deeper problem within Laidlaw & Company’s business practices and ethics. Specifically, Laidlaw & Company has repeatedly proven in the past that they will exploit anyone or anything in order to make a profit for themselves, regardless of the damage it may cause. This tendency towards the unethical is evident in their dealings with Relmada Therapeutics, but other financial disputes as well. It’s for this reason that the court has had no issue in warning Matthew Eitner and James Ahern to cease spreading false information to try and justify their actions.